Imagine a world without the constant fear of HIV. It's closer than you think, but a critical turning point could determine if this dream becomes reality or remains just out of reach. A groundbreaking HIV prevention drug, lenacapavir, offering near-complete protection with just two injections a year, has been approved. Now, after swift approval in wealthy nations, this potentially life-saving medication is beginning to reach countries that desperately need it.
Five months after receiving the green light in the United States and becoming available in many high-income countries, lenacapavir is being rolled out in Eswatini and Zambia, two African nations disproportionately affected by HIV. The U.S. State Department recently announced that each country has received an initial shipment of 500 doses of this game-changing drug, manufactured by Gilead Sciences. According to Science magazine, lenacapavir represents a genuine breakthrough in HIV prevention. The drug offers a revolutionary approach: just two injections annually provide almost total protection against HIV infection.
"This is somewhat unprecedented, to see an innovation in global health move this fast to low- and middle-income countries," explains Mitchell Warren, Executive Director of AVAC (AIDS Vaccine Advocacy Coalition), a leading global HIV prevention organization. "Obviously very small supplies, really just a down payment, but they're the first of what we think to be many doses in these two countries and in other countries."
These initial deliveries represent a small but crucial step toward the ambitious goal of providing at least 2 million doses to countries with the highest HIV burden, primarily in Africa, by 2028. This initiative is a collaborative effort between the Global Fund (a major donor in the fight against HIV, tuberculosis, and malaria), Gilead Sciences, and the U.S. State Department.
But here's where it gets controversial... This breakthrough arrives at a particularly challenging moment. "Just as we've seen some of the most dramatic political and economic challenges in the AIDS response," notes Warren. He points out that disruptions in healthcare, likely increasing the overall HIV burden, are compounded by the lingering effects of foreign aid cuts implemented by the Trump administration. These cuts, Warren argues, have weakened the very systems and programs that are best positioned to deliver lenacapavir to those most vulnerable. "We are starting from a deficit that we didn't have to, that was a making entirely of the U.S. government's own."
Rapid Delivery: A Race Against Time
The State Department initially announced its investment in lenacapavir in September, pledging to provide up to 2 million doses by 2028. "We think we're going to hit that target sometime in mid- to early 2027 [and] we're going to be procuring more than half a million doses collectively next year," said Jeremy Lewin, a senior official for Foreign Assistance, Humanitarian Affairs and Religious Freedom at the State Department, during a recent press briefing.
Gilead is providing the initial 500 doses at cost, foregoing any profit, according to CEO Daniel O'Day. The company intends to supply up to 2 million doses in total before licensed generic manufacturers become operational. However, the exact number of doses currently available remains unclear. "We do have supply to send to markets when they have the appropriate regulatory approval, and replenishment for Eswatini and Zambia," O'Day stated.
Since the FDA granted lenacapavir approval in June (followed by approvals from the World Health Organization and the European Medicines Agency in July), Gilead has been actively seeking regulatory approvals across sub-Saharan Africa. Zambia and South Africa have already approved the drug. Lewin clarified that the U.S. is not planning to fund doses for South Africa, encouraging them to finance the drug for their own population. Eswatini's Ministry of Health issued a separate import authorization, equivalent to approval.
So, where will lenacapavir go next? Gilead has applications pending in Botswana, Kenya, Malawi, Namibia, Rwanda, Tanzania, Uganda, and Zimbabwe, with plans for further expansion. O'Day emphasized that the company is prioritizing "18 high burden countries representing 70% of the HIV epidemic."
And this is the part most people miss... Distribution is key. Getting the drug into the hands (or rather, arms) of those who need it is paramount to curbing the epidemic. While health ministries will bear the primary responsibility, many governments rely on community organizations and non-governmental organizations for assistance. Lewin highlighted that this approach aligns with the U.S. America First Global Health Strategy's goal of enhancing national government "self-reliance."
However, many of these healthcare systems depend on external organizations that have faced defunding or weakening due to the previous administration's foreign aid cuts, according to Warren. He cited a program his own organization, AVAC, helped implement as an example. This program aimed to strengthen health systems' capacity to deliver injectable HIV drugs like lenacapavir, which require more complex distribution than pills. The program was frozen in January and has yet to fully recover.
"If you don't have the program that meets people where they are, then those doses aren't going to get used," Warren cautions. "There's a lot of history of global health products that everyone thinks are exciting, and then they sit in store rooms because we didn't build the program to deliver them." The success of this breakthrough drug hinges not only on its effectiveness but also on the ability to overcome logistical challenges and political obstacles to ensure it reaches those who need it most. Will the international community rise to the occasion? Will previously strained relationships be repaired to ensure efficient distribution? And crucially, how can we ensure that past mistakes aren't repeated, preventing this potentially life-saving drug from sitting unused? Share your thoughts and concerns in the comments below.
